Appraising risk in active surveillance of localized prostate cancer.


Journal

Health expectations : an international journal of public participation in health care and health policy
ISSN: 1369-7625
Titre abrégé: Health Expect
Pays: England
ID NLM: 9815926

Informations de publication

Date de publication:
10 2019
Historique:
received: 30 07 2018
revised: 07 04 2019
accepted: 25 04 2019
pubmed: 17 5 2019
medline: 9 9 2020
entrez: 17 5 2019
Statut: ppublish

Résumé

Men diagnosed with low-risk prostate cancer are typically eligible for active surveillance of their cancer, involving monitoring for cancer progression and making judgements about the risks of prostate cancer against those of active intervention. Our study examined how risk for prostate cancer is perceived and experienced by patients undergoing active surveillance with their clinicians, how risk is communicated in clinical consultations, and the implications for treatment and care. Participants were nine patients and three clinicians from a university hospital urology clinic. A staged, qualitative, multi-method data collection approach was undertaken, comprising: observations of consultations; patient and clinician interviews; and patient surveys. The three data sets were analysed separately using thematic analysis and then integrated to give a comprehensive view of patient and clinician views. Thirty data points (eight patient surveys; 10 observations of consultations between patients and clinicians; 10 patient interviews; and two clinician interviews) combined to create a detailed picture of how patients perceived and appraised risk, in three themes of "Making sense of risk", "Talking about risk" and "Responding to risk". Effective risk communication needs to be finely tuned and timed to individual patient's priorities and information requirements. A structured information exchange process that identifies patients' priorities, and details key moments in risk assessment, so that complexities of risk are discussed in ways that are meaningful to patients, may benefit patient care. These findings could inform the development of patient-centric risk assessment procedures and service delivery models in prostate cancer care more broadly.

Identifiants

pubmed: 31095822
doi: 10.1111/hex.12912
pmc: PMC6803412
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1028-1039

Informations de copyright

© 2019 The Authors Health Expectations published by John Wiley & Sons Ltd.

Références

Eur Urol. 2018 Sep;74(3):261-280
pubmed: 29598981
BJU Int. 2002 Aug;90(3):257-64
pubmed: 12133062
Cancer. 2008 Apr 15;112(8):1650-9
pubmed: 18306379
Med Decis Making. 2010 Sep-Oct;30(5 Suppl):96S-105S
pubmed: 20881158
J Urol. 2015 Nov;194(5):1247-52
pubmed: 26055824
Eur Urol. 2015 Jun;67(6):993-1005
pubmed: 25616709
Rev Hum Factors Ergon. 2013 Oct;8(1):235-276
pubmed: 24999307
Arch Intern Med. 2009 Sep 28;169(17):1603-10
pubmed: 19786680
BJU Int. 2012 Apr;109 Suppl 3:40-3
pubmed: 22458492
N Engl J Med. 2011 May 5;364(18):1708-17
pubmed: 21542742
J Natl Cancer Inst. 2011 Oct 5;103(19):1436-43
pubmed: 21931068
J Adv Nurs. 1998 Sep;28(3):631-41
pubmed: 9756233
Ann Intern Med. 2010 Nov 16;153(10):661-5
pubmed: 21079223
Med J Aust. 2018 Jun 4;208(10):439-443
pubmed: 29793403
Qual Health Res. 2018 Jan;28(1):30-46
pubmed: 28938853
BMJ Open. 2017 Feb 22;7(2):e014512
pubmed: 28399515
Ann Intern Med. 2014 Sep 16;161(6):441-2
pubmed: 25222389
Psychooncology. 2018 Jan;27(1):325-332
pubmed: 28612468
Patient Educ Couns. 2012 Jun;87(3):369-74
pubmed: 22177658
BJU Int. 2007 Sep;100(3):544-51
pubmed: 17532857
CA Cancer J Clin. 2015 May-Jun;65(3):239-51
pubmed: 25772796
Cancer Invest. 2001;19(7):684-91
pubmed: 11577809
F1000Res. 2014 Feb 13;3:42
pubmed: 25075286
J Urol. 2012 Nov;188(5):1667-75
pubmed: 22998919
Health Expect. 2019 Oct;22(5):1028-1039
pubmed: 31095822
Eur Urol. 2012 Jun;61(6):1079-92
pubmed: 22424666
Cancer Sci. 2014 Aug;105(8):1079-85
pubmed: 24890684
Cancer Epidemiol Biomarkers Prev. 2016 Aug;25(8):1240-50
pubmed: 27257092
Int J Pharm Pract. 2010 Oct;18(5):260-8
pubmed: 20840681
J Adv Nurs. 2003 Jul;43(1):28-42
pubmed: 12801394
Cancer. 2006 May 1;106(9):1865-74
pubmed: 16568450
BJU Int. 2002 Feb;89(3):255-60
pubmed: 11856106
Curr Oncol. 2015 Dec;22(6):e462-9
pubmed: 26715884

Auteurs

Anne Hogden (A)

Faculty of Medicine and Health Sciences, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.
Tasmanian School of Business and Economics, Australian Institute of Health Service Management, University of Tasmania, Sydney, New South Wales, Australia.

Kate Churruca (K)

Faculty of Medicine and Health Sciences, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.

Frances Rapport (F)

Faculty of Medicine and Health Sciences, Australian Institute of Health Innovation, Macquarie University, Sydney, New South Wales, Australia.

David Gillatt (D)

Faculty of Medicine and Health Sciences, Macquarie University, Sydney, New South Wales, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH